Jeffrey G. Lamothe - Mar 2, 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
EVP, COO
Signature
/s/ SoYoung Kwon, Attorney-In-Fact
Stock symbol
APVO
Transactions as of
Mar 2, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 04:35 PM
Previous filing
Aug 9, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +3 +9.68% 34 Mar 2, 2025 Direct F1
transaction APVO Common Stock Options Exercise +2 +5.88% 36 Mar 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -3 -42.86% $0.00 4 Mar 2, 2025 Common Stock 3 Direct F1, F2
transaction APVO Restricted Stock Unit Options Exercise $0 -2 -100% $0.00 0 Mar 3, 2025 Common Stock 2 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On March 3, 2023, the reporting person was granted 16,500 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
F3 On June 7, 2022, the reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.